Personalised medicine
Tailoring cancer treatment to individual needs.
Personalised medicine uses detailed information about a person’s cancer to improve treatment.
Cancer cells have unique genetic changes, or mutations. These differences mean that each person’s tumour has its own genetic makeup, influencing how the tumour behaves and responds to treatment. Personalised medicine aims to develop and match specific treatments that work best for these specific genetic changes.
Professor Richard Gilbertson co-leads the Minderoo Precision Brain Tumour Programme, using genomic data to guide treatment for aggressive brain cancers. This programme will trial genomic-based therapies with 225 patients at Addenbrooke’s Hospital, aiming to integrate precision medicine into routine NHS care.
The Brenton Group has worked with NHS England to incorporate whole-genome sequencing into treatment plans for High Grade Serous Ovarian Cancer, using genetic signatures to guide decisions.
The Personalised Breast Cancer Program, founded by the Caldas Group and now led by our Affiliated Clinical Faculty member Jean Abraham, uses real-time genome sequencing to tailor patient care and has expanded to n sites nationwide.
We aim to further explore tumour diversity and develop genomics to predict both relapse and effective treatments, improving patient outcomes through personalised treatment.
Impact
See all case studies-
Increasing the uptake of genetic testing with ovarian cancer patients
The DEMO project aims to increase genetic testing for ovarian cancer patients by addressing language barriers and providing tailored resources.
Find out more -
Personalising treatment for ovarian cancer patients: BriTROC-2
BriTROC-2 is a nationwide project developing personalised treatments for women diagnosed with High Grade Serous Ovarian Cancer.
Find out more
Related News
See all news-
World first trial to revolutionise treatment of brain cancer
23rd October 2024
A pioneering research study will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.
Find out more -
PIONEER trial of new treatment for breast cancer patients
11th December 2023
Trial testing a potential new treatment combination for post-menopausal women with hormone driven breast cancer reports positive findings.
Find out more -
Identifying tumour characteristics to predict immunotherapy response
6th September 2023
Tumour characteristics could be used to predict whether patients with an aggressive subtype of breast cancer are able to respond to immunotherapy.
Find out more